Credit: Getty Images. Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium ...

ORLANDO — Use of adjunctive sodium-glucose cotransport (SGLT) inhibitors along with insulin could herald a new era of improved glycemic control in type 1 diabetes, but there is concern about ...

Clinicians should consider incorporating sodium-glucose cotransport 2 inhibitors into the management of acute kidney disease and type 2 diabetes, according to investigators. Sodium-glucose ...

also found that alpha cells express the sodium–glucose cotransporters ... Why would a cotransport system that concentrates glucose be used to control glucagon secretion, which is important ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

in combination with empagliflozin (Jardiance®), a sodium-glucose cotransport-2 (SGLT2) inhibitor, in patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The Phase 2a study ...

SGLT2 inhibitors work in a different way to lower your blood sugar. They curb the action of proteins called "sodium-glucose cotransporter 2" that help your kidneys reabsorb glucose (sugar ...

In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.